Journal of Cancer Therapy
Vol.8 No.6(2017), Paper ID 77062, 18
pages
DOI:10.4236/jct.2017.86048
Inhibition of Neuroblastoma Cell Growth by Difluoromethylornithine (DFMO) and Bortezomib through Suppression of LIN28 and MYCN
Maria E. Rich, Ping Zhao, Abhinav B. Nagulapally, Jeffrey Bond, Giselle L. Saulnier Sholler
Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
Pediatric Oncology Research Program, Helen DeVos Children’s Hospital, Grand Rapids, MI, USA
College of Human Medicine, Michigan State University, Grand Rapids, MI, USA
Copyright © 2017 Maria E. Rich, Ping Zhao, Abhinav B. Nagulapally, Jeffrey Bond, Giselle L. Saulnier Sholler et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Rich, M. , Zhao, P. , Nagulapally, A. , Bond, J. and Sholler, G. (2017) Inhibition of Neuroblastoma Cell Growth by Difluoromethylornithine (DFMO) and Bortezomib through Suppression of LIN28 and MYCN.
Journal of Cancer Therapy,
8, 561-578. doi:
10.4236/jct.2017.86048.